China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
0 hedge funds and large institutions have $0 invested in China Biologic Products Holdings, Inc. in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 84 closing their positions.
100% less funds holding
Funds holding: 86 → 0 (-86)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $1.74B → $0 (-$1.74B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 84
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$351M |
| 2 |
Temasek Holdings
Singapore
|
-$147M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$140M |
| 4 |
AC
Athos Capital
Hong Kong
|
-$110M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$99.3M |
CBPO Hedge Fund Activity: Q2 2021 in Review
0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2021, worth a combined $0 — down 100% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of CBPO and 0 opened new positions — a net loss of 84 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was HHLR Advisors, exiting entirely with an estimated $351M sold.
- 0 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2021, down from 86 in Q1 2021.
- Funds reported $0 of China Biologic Products Holdings, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2021 and 84 closed out, a net change of -84 holders.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2021 was HHLR Advisors, an estimated $351M sold.
Based on aggregated 13F filings for Q2 2021.